Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)

被引:12
作者
Batteux, Benjamin [1 ,2 ,3 ,4 ]
Bennis, Youssef [1 ,3 ]
Bodeau, Sandra [1 ,3 ]
Masmoudi, Kamel [1 ]
Hurtel-Lemaire, Anne-Sophie [1 ]
Kamel, Said [3 ,5 ]
Gras-Champel, Valerie [1 ,3 ]
Liabeuf, Sophie [1 ,3 ]
机构
[1] Amiens Univ, Dept Pharmacol, Med Ctr, F-80054 Amiens, France
[2] St Quentin Med Ctr, Dept Rheumatol, F-02321 St Quentin en Yvelines, France
[3] Jules Verne Univ Picardie, MP3CV Lab, EA7517, F-80054 Amiens, France
[4] Amiens Picardie Univ, RECIF, Med Ctr, F-80054 Amiens, France
[5] Amiens Univ, Biochem Lab, Med Ctr, F-80000 Amiens, France
关键词
Osteoporosis; Drug; Pharmacology; Pharmacoepidemiology; Pharmacovigilance; BONE-MINERAL DENSITY; RHEUMATOID-ARTHRITIS PATIENTS; LOW-DOSE METHOTREXATE; POSTMENOPAUSAL WOMEN; FRACTURE RISK; VITAMIN-A; PSYCHOTROPIC MEDICATIONS; INADEQUATE RESPONSE; MULTIPLE-SCLEROSIS; SIGNAL GENERATION;
D O I
10.1016/j.bone.2021.116137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Bone remodeling is a complex process, and many conditions (including drug exposure) lead to osteoporosis. Here, we sought to detect new disproportionality signals for drugs associated with osteoporosis. Methods: We performed a disproportionality analysis of the World Health Organization's VigiBase (R) pharmacovigilance database through April 12, 2020. The frequency of reports on osteoporosis for all identified drug classes was compared with that for all other drugs and quoted as the reporting odds ratio (ROR) [95% confidence interval (CI)]. Results: Of the 7,594,968 cases spontaneously recorded to VigiBase (R), 4758 concerned osteoporosis. New disproportionality signals with a pharmacologically plausible mechanism were found for drugs used in neurology (levodopa (ROR [95%CI]: 10.18 [4.33-25.10]), selective serotonin agonists (4.22 [2.34-7.00]) and memantine (4.10 [1.56-8.93])), hematology (romiplostim (4.93 [1.15-21.10])), pulmonology (macitentan (3.02 [1.84-4.90])), ophthalmology (ranibizumab (3.31 [1.00-10.51])) and rheumatology (tofacitinib (3.65 [3.00-4.40])). The robustness of these new results is supported by the significant RORs for the vast majority of drugs already known to induce osteoporosis and/or increase the fracture risk, namely glucocorticoids, gonadotropin-releasing hormone analogs, anti-aromatases, androgen receptor blockers, thyroid hormones, proton pump inhibitors, thiazolidinediones, vitamin K antagonists, loop diuretics, protease inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, and enzyme-inducing antiepileptics including barbiturates and derivatives, hydantoin derivatives, carboxamide derivatives and fatty acid derivatives. Conclusion: We established up a comprehensive list of drugs potentially associated with osteoporosis and highlighted those with pharmacologically plausible mechanisms leading to bone fragility. Our results might pave the way for additional exploration of these mechanisms.
引用
收藏
页数:11
相关论文
共 32 条
  • [21] Myositis associated with Immune Checkpoint Inhibitors: A pharmacovigilance study using the World Health Organization's adverse drug reactions database
    Ladhari, C.
    Nguyen, T.
    Maria, A.
    Palassin, P.
    Quantin, X.
    Lesage, C.
    Taieb, G.
    Ayrignac, X.
    Rullier, P.
    Lambotte, O.
    Guilpain, P.
    Hillaire-Buys, D.
    Faillie, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 103 - 103
  • [22] Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system
    Yang, Zeping
    Tang, Kejing
    Chen, Jie
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1439 - 1446
  • [23] A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database
    Rong, Li
    Xie, Mengyuan
    Jiang, Manxue
    Qiu, Hongyu
    Kong, Lingti
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (08) : 1816 - 1826
  • [24] Post-marketing safety of pimavanserin: a real-world pharmacovigilance study based on the FDA adverse event reporting system (FAERS)
    Liu, Dong
    Zhang, Xueni
    Xu, Haiyan
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [25] Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database
    Zou, Dan
    Hu, Qiaozhi
    Liu, Ying
    Yu, Lei
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (06) : 1419 - 1426
  • [26] Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization
    Zheng, Yi
    Zhou, Wenli
    Guo, Xiaojing
    Chi, Lijie
    Chen, Chenxin
    Guo, Zhijian
    Liang, Jizhou
    Wei, Lianhui
    Chen, Xiao
    Ye, Xiaofei
    He, Jia
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (08) : 1127 - 1133
  • [27] Association between antidepressant use and delirium in older adults: an analysis of the World Health Organization's global pharmacovigilance database
    Minoc, Elise-Marie
    Villain, Cedric
    Benbrika, Soumia
    Chretien, Basile
    Descatoire, Pablo
    Heraudeau, Marie
    Sassier, Marion
    Pierre, Melissa
    Martinaud, Olivier
    Dolladille, Charles
    Lelong-Boulouard, Veronique
    BMC GERIATRICS, 2024, 24 (01)
  • [28] Adverse drug reactions associated with ivermectin use for COVID19 reported in the World Health Organization's pharmacovigilance database
    Campillo, Jeremy T.
    Faillie, Jean-Luc
    THERAPIE, 2022, 77 (06): : 747 - 749
  • [29] Anticancer drug-induced life-threatening ventricular arrhythmias: a World health Organization pharmacovigilance study
    Salem, Joe-Elie
    Nguyen, Lee S.
    Moslehi, Javid J.
    Ederhy, Stephane
    Lebrun-Vignes, Benedicte
    Roden, Dan M.
    Funck-Brentano, Christian
    Gougis, Paul
    EUROPEAN HEART JOURNAL, 2021, 42 (38) : 3915 - +
  • [30] IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis
    Alroobaea, R.
    Rubaiee, S.
    Hanbazazah, A. S.
    Jahrami, H.
    Garbarino, S.
    Damiani, G.
    Wu, J.
    Bragazzi, N. L.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (11) : 4074 - 4081